News | July 09, 2009

Hospital Care for Heart Attack, Heart Failure Varies Across Nation

July 9, 2009 – The 30-day mortality and readmission rates for acute care of heart attack and heart failure patients vary significantly from hospital to hospital across the nation, according to a new study published in a current issue of Circulation, the journal of the American Heart Association.

In the article “Cardiovascular Quality and Outcomes,” researchers analyzed findings from the 2009 Centers for Medicare and Medicaid Services (CMS) 30-day outcomes report for acute myocardial infarction and heart failure, part of the CMS Hospital Compare quality initiative.

Researchers reviewed three years of experience (July 2005 to June 2008) of Medicare fee-for-service patients with heart failure and heart attack. Calculating 30-day death and readmission rates, based on nearly 600,000 heart attack admissions and more than 1 million heart failure admissions at almost 5,000 hospitals nationwide, they found:

• The average 30-day death rate for heart attack was 16.6 percent.

• The average rate of heart attack readmission was 19.9 percent.

• The average 30-day death rate for heart failure was 11.1 percent and 24.4 percent for readmission.

The researchers said their findings represent an opportunity for improvement.

"If we just look at readmission, one in four patients who has heart failure and one in five who has a heart attack is back in the hospital within 30 days for readmission," said Harlan M. Krumholz, M.D., the study's lead author, professor of medicine and outcomes researcher at Yale University School of Medicine in New Haven, Conn. "Variations in those rates from hospital to hospital tell yet another story. What we're seeing is that, for example, for heart attack patients, the best hospital in the country has a 30-day mortality rate of only about 11 percent and the hospital with the highest rate in the country has a rate of almost 25 percent."

Researchers also found the heart failure death rate ranged from 6.6 percent to 19.8 percent. Readmission for heart attack ranged from 15.3 percent to 29.4 percent. Readmission for heart failure ranged from 15.9 percent to 34.4 percent.

"This suggests that patients' outcomes are dependent, at least in part, on the hospital that provides their care," Dr. Krumholz said. "What we seem to have here are differences among hospitals that are based on quality and the systems that they have in place. If we could better understand how the best hospitals achieve their results and help the hospitals that are not doing as well improve, we could save many more lives."

He said the release and analysis of the CMS data may now make that possible.

"The hope is that this information will stimulate constructive engagement by the healthcare community to find ways to improve performance and patient outcomes," he said.

The U.S. Centers for Medicare & Medicaid Services funded the study.

For more information: www.americanheart.org


Related Content

News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
Subscribe Now